Pathological haemostasis and 'prothrombotic state' in Behçet's disease

Thrombosis Research

Volumn 105, Issue 2, 2002, Pages 125-133

  Kiraz, Sedat ^a   Ertenli, Ihsan ^a   Ozturk M Akif ^a   Haznedarolu, Ibrahim C ^a   Çelik, Ismail ^a   Çalgüneri, Meral ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Beh et's disease; Coagulation; Endothelium; Fibrinolysis; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; BLOOD CLOTTING INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; RIDOGREL; THROMBIN ANTITHROMBIN COMPLEX; VAPIPROST;

BEHCET DISEASE; BLOOD CLOTTING; CELL DAMAGE; CLINICAL FEATURE; DISEASE MARKER; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FIBRINOLYSIS; GENETIC DISORDER; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; THROMBOSIS; TREATMENT OUTCOME; VASCULAR DISEASE; BLOOD; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW; THROMBOPHILIA; VASCULAR ENDOTHELIUM;

BEHCET SYNDROME; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HUMANS; THROMBOPHILIA; THROMBOSIS;

EID: 0037087232     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00006-3     Document Type: Review

References (87)

1. Über rezidiverende aphthöse durch ein virus verursachte geschwüre am mund, am auge, und an den genitalien
2. Behçet's disease
3. Vasculitis in Behçet's disease
4. Haemostasis, thrombosis, and endothelium in Behçet's disease
5. Coagulation and fibrinolytic activity in Behçet's disease
6. Vascular involvement in Behçet's disease
7. Gastrointestinal manifestations of Behçet's disease
8. Intracranial hypertension in Behçet's disease: Demonstration of sinus occlusion with use of digital subtraction angiography
9. Intracardiac thrombus in Behçet's disease: A systematic review
10. Pathologic features of Behçet's syndrome: A review of Japanase autopsy registry data
11. Behçet's syndrome associated with minimal change glomerulonephritis and renal ein thrombosis
12. Acute myocardial infarction and recurrent ventricular arrhythmias in Behcet's syndrome
13. Epidemiology and pathogenesis of the ocular and cerebral forms of Behçet's disease
14. Structure and function of von Willebrand factor
15. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood
16. Overview of hemostasis
17. Antithrombin III
18. Tissue factor pathway inhibitor and the current concept of blood coagulation
19. Fibrin clot formation and lysis: Basic mechanisms
20. The endothelium and thrombosis
21. Endothelial cells in physiology and in the pathophysiology of vascular disorders
22. Arterial thrombosis leading to intestinal infarction in a patient with Behçet's disease associated with protein C deficiency
23. Extensive venous thrombosis in a case of Behçet's disease associated with heterozygous protein C deficiency
24. Behçet syndrome associated with protein S deficiency
25. Protein S deficiency and antibodies to protein S in patients with Behçet's disease
26. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behçet's disease
27. Antithrombin III, protein C and protein S plasma levels in patients with Behçet's disease
28. Protein C and protein S activities in Behçet's disease as risk factors of thrombosis
29. Comparison of coagulation parameters for healthy subjects and Behçet disease patients with and without vascular involvement
30. Haemostatic markers of procoagulant inbalance in Behçet's disease
31. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis
32. Coagulation factor V gene mutation increases the risk of venous thrombosis in Behçet's disease
33. Activated protein C resistance caused by factor V Arg506Gln mutation has no role in thrombotic manifestations of Behçet's disease
34. Factor V Leiden mutation in patients with Behçet's disease
35. Association of factor V Leiden with Behçet's disease
36. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombosis in Behçet's disease
37. Activated protein C resistance in Behçet's disease
38. A common genetic variation in 3′-untranslated region region of prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
39. The prothrombin 20210 G to A variation and thrombosis
40. Procoagulant mutations and venous thrombosis in Behçet's disease
41. Intracardiac thrombosis in a case of Behçet's disease associated with the prothrombin 20210G-A mutation
42. 20210 mutation in Behçet's disease
43. Hyperhomocysteinaemia and activated protein C resistance in Behçet's disease
44. Impaired haemostatic kinetics and endothelial function in Behçet's disease
45. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
46. Changes in the concentration and distribution of TFPI in Behçet's disease and SLE: Impact on the prethrombotic state
47. Anticardiolipin antibodies in Adamantiades-Behçet's disease
48. Anticardiolipin antibodies occurrence in Behçet's syndrome
49. Anticardiolipin antibody and significance with respect to clinical signs in Behçet's disease
50. Anticardiolipin antibodies in Behçet's disease
51. Thrombolytic therapy in pulmonary embolism of Behçet's disease
52. Plasminogen activator activity levels in patients with Behçet's syndrome
53. Evaluation of recurrent thrombosis and hypercoagulability
54. Antibodies to endothelial cells in patients with Behçet's disease
55. Antibodies to endothelial cells in Behçet's disease: Cell-binding heterogeneity and association with clinical activity
56. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease
57. Circulating thrombomodulin as a clue of endothelial damage in Behçet's disease
58. Soluble thrombomodulin and fibrinolysis in Behçet's disease
59. Selectin adhesion molecule in Behçet's disease
60. Plasma prostacyclin levels in Behçet's disease
61. Impaired prostacyclin synthesis by vessel walls in Behçet's disease
62. Plasma prostacyclin levels in Behçet's disease
63. Eicosanoids in the prethrombotic state of Behçet's disease
64. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome
65. Interactions of nitric oxide and superoxide dismutase in Behçet's disease
66. Nitric oxide and inflammatory joint diseases
67. Criteria for diagnosis of Behçet's disease
68. Behçet's syndrome
69. Kinetics of inhibition of thrombin by hirudin
70. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin
71. Argatroban: A synthetic thrombin inhibitor of low relative molecular mass
72. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes
73. Highly selective tripeptide thrombin inhibitors
74. A peptide derived from a tissue factor loop region functions as a tissue factor-factor VIIa antagonist
75. Synthetic peptide analogs of tissue factor and factor VII which inhibit factor Xa formation by the tissue factor/factor VIIa complex
76. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway
77. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model
78. Ancylostoma caninum anticoagulant peptide: A hookworm-derived inhibitor of human coagulation factor Xa
79. Recombinant human protein C derivatives: Altered response to calcium resulting in enhaced activation by thrombomodulin
80. Direct expression of recombinant activated human C. protein, a serine protease
81. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice
82. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III
83. Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator
84. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits
85. Evidence that prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A2 production
86. 2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism study (CARPORT)
87. 2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction: The Ridogrel versus Aspirin Patency Trial (RAPT)